Secondary Logo

Journal Logo

UpToDate®

doi: 10.1097/01.COT.0000521874.45674.86
News
Free

UpToDate® and Oncology Times are collaborating to present select content synopses on “What's New in Oncology.” UpToDate is an evidence-based, clinical support resource used worldwide by healthcare practitioners to make decisions at the point of care. For complete, current ‘What's New’ content, or to become a subscriber for full content access, go towww.uptodate.com. “What's New” abstract information is free for all healthcare practitioners.

Back to Top | Article Outline

Adjuvant Capecitabine for Residual HER2-Negative Breast Cancer After Neoadjuvant Chemotherapy

In a randomized trial of approximately 900 patients with HER2-negative breast cancer and residual disease after neoadjuvant chemotherapy, patients in the adjuvant capecitabine group, compared with placebo, had higher rates of five-year disease-free survival (74 versus 68 percent) and overall survival (89 versus 84 percent). Subgroup analyses suggested that these findings were driven primarily by outcomes in patients with triple-negative disease. Toxicities were higher in patients receiving capecitabine, including diarrhea, neutropenia, and hand-foot syndrome. Given these results, we now suggest capecitabine for patients with residual HER2-negative breast cancer after neoadjuvant therapy, though observation is also acceptable, given the increased toxicities associated with adjuvant capecitabine.

Back to Top | Article Outline

Risk of Colon Cancer in Patients With Diverticulitis

The utility of routine colonoscopy after acute diverticulitis is debated. An analysis of data from a Danish registry showed that patients hospitalized for diverticulitis were twice as likely to develop colon cancer over the 18-year study period as those without diverticulitis, and over 50 percent of colon cancers were diagnosed within one year of diagnosis of diverticulitis. This study underscores the importance of endoscopic surveillance in patients with diverticular disease and supports our recommendation for performing a colonoscopy after the complete resolution of an episode of acute diverticulitis in patients who have not had a colonoscopy within a year.

Back to Top | Article Outline

Sentinel Lymph Node Biopsy in Endometrial Cancer

Sentinel lymph node biopsy for staging endometrial carcinoma is increasingly performed instead of selective or extended nodal dissection. In the largest multicenter prospective study of the procedure in over 300 women with clinical stage I endometrial carcinoma, successful mapping of at least one sentinel lymph node was achieved in 86 percent and the sensitivity of the sentinel lymph node was 97 percent. Nevertheless, we believe further study is needed before sentinel lymph node biopsy is established as a reasonable alternative to full pelvic lymphadenectomy in endometrial carcinoma.

Back to Top | Article Outline

Guideline on Use of Molecular Markers in Colorectal Cancer

The prognostic value of a wide variety of potentially clinically applicable molecular markers has been extensively studied in colorectal cancer (CRC). An updated multisociety United States guideline recommends testing for DNA mismatch repair protein (MMR) status to identify patients at high risk for Lynch syndrome, expanded or extended RAS testing for patients being considered for therapy targeting the epidermal growth factor receptor (EGFR), and BRAF V600 mutational analysis for deficient MMR tumors with loss of MLH1 expression to evaluate for Lynch syndrome risk. They also concluded that there was insufficient evidence to use BRAF mutational status as a predictive molecular biomarker for response to anti-EGFR therapies. However, this is a controversial area. UpToDate recommends not using EGFR inhibitors in patients with a tumoral BRAF V600E mutation.

Back to Top | Article Outline

Laparoscopic Interval Debulking After Neoadjuvant Chemotherapy for Ovarian Cancer

Women with stage IIIC or IV ovarian cancer and unresectable disease may be candidates for neoadjuvant chemotherapy (NACT) followed by interval debulking, typically performed with laparotomy. Results of a large retrospective study suggest that laparoscopy could be a minimally invasive option for such debulking. Compared with laparotomy, laparoscopy was associated with similar three-year overall survival rates (47.5 versus 52.6 percent), similar suboptimal debulking rates (20.0 versus 22.6 percent), a shorter hospital stay by one day, and similar 30-day readmission rates. Further study is needed to evaluate whether short-term morbidity is reduced with use of laparoscopy.

Disclaimer: This content is provided for reference purposes only and represents a portion of the UpToDate topic. You may not rely on the content or any information cited here as being applicable to specific patient circumstances. All topics are updated as new evidence becomes available and our peer review process is complete. Subscribe towww.uptodate.comfor current content and recommendations.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Home  Clinical Resource Center
Current Issue       Search OT
Archives Get OT Enews
Blogs Email us!